NCT02854839View on ClinicalTrials.gov

A Study of MG4101 (Allogeneic Natural Killer Cell) for Intermediate-stage of Hepatocellular Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

November 28, 2016

Primary Completion Date

September 27, 2018

Study Completion Date

September 17, 2019

Conditions
Hepatocellular Carcinoma
Interventions
BIOLOGICAL

MG4101

MG4101 is ex vivo-expanded, allogeneic natural killer cells. MG4101 were manufactured from normal healthy donor who underwent lymphopheresis under good manufacturing practice (GMP) conditions.

Trial Locations (6)

03080

Seoul National University Hospital, Seoul

05505

Seoul Asan Medical center, Seoul

06351

Samsung Medical Center, Seoul

Unknown

Korea Univ. Guro Hospital, Seoul

Severance hospital, Seoul

Ajou Univ. Hospital, Suwon

Sponsors
All Listed Sponsors
lead

GC Cell Corporation

INDUSTRY